Pyroptosis-related gene signatures are associated with prognosis and tumor microenvironment infiltration in head and neck cancer.
head and neck squamous cell carcinoma
immunotherapy
mutation burden
pyroptosis
tumor microenvironment
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
31
07
2023
revised:
25
09
2023
accepted:
26
09
2023
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Recent studies have highlighted the biological significance of pyroptosis in cancer development. Nevertheless, it is still uncertain if pyroptosis also plays a part in immune modulation and the creation of the tumor microenvironment (TME). The pyroptosis regulatory genes (PRGs) were comprehensively assessed in 1938 head and neck cancer samples, and systematically correlated these modification patterns with the infiltration characteristics of TME cells. The unsupervised consensus analysis method was used to identify specific pyroptosis clusters. The single-sample gene set enrichment analysis and CIBERSOFT algorithms were used to evaluate the infiltration levels of various immune cell subsets. A principal component analysis algorithm was used to construct the pyrolysis potential index (PPI) to quantify the pyrolysis regulation patterns in head and neck squamous cell carcinoma (HNSC). Pyrophosphate regulatory genes (PRGs) are often upregulated in tumors due to mutations. PRGs relate to various clinical outcomes and pathways. Molecular subtyping identified pyroptosis patterns, which align with three tumor immunophenotypes: immune-inflamed, immune-excluded, and immune-desert. The PPI measures pyrolysis roles, showing higher PPI in tumor samples linked to subtypes and clinical characteristics. Lower PPI correlates with longer survival, increased immune activity, more tumor mutations, high PD-L1 expression, and mutations in significant genes like PIK3CA. Such patients also experience enhanced immune responses in immunotherapy trials. We conducted a comprehensive examination of pyroptosis in HNSC and developed a PPI indicator that shows a strong correlation with the variety and intricacy of the TME.
Sections du résumé
Background and Aims
UNASSIGNED
Recent studies have highlighted the biological significance of pyroptosis in cancer development. Nevertheless, it is still uncertain if pyroptosis also plays a part in immune modulation and the creation of the tumor microenvironment (TME).
Methods
UNASSIGNED
The pyroptosis regulatory genes (PRGs) were comprehensively assessed in 1938 head and neck cancer samples, and systematically correlated these modification patterns with the infiltration characteristics of TME cells. The unsupervised consensus analysis method was used to identify specific pyroptosis clusters. The single-sample gene set enrichment analysis and CIBERSOFT algorithms were used to evaluate the infiltration levels of various immune cell subsets. A principal component analysis algorithm was used to construct the pyrolysis potential index (PPI) to quantify the pyrolysis regulation patterns in head and neck squamous cell carcinoma (HNSC).
Results
UNASSIGNED
Pyrophosphate regulatory genes (PRGs) are often upregulated in tumors due to mutations. PRGs relate to various clinical outcomes and pathways. Molecular subtyping identified pyroptosis patterns, which align with three tumor immunophenotypes: immune-inflamed, immune-excluded, and immune-desert. The PPI measures pyrolysis roles, showing higher PPI in tumor samples linked to subtypes and clinical characteristics. Lower PPI correlates with longer survival, increased immune activity, more tumor mutations, high PD-L1 expression, and mutations in significant genes like PIK3CA. Such patients also experience enhanced immune responses in immunotherapy trials.
Conclusion
UNASSIGNED
We conducted a comprehensive examination of pyroptosis in HNSC and developed a PPI indicator that shows a strong correlation with the variety and intricacy of the TME.
Identifiants
pubmed: 37841942
doi: 10.1002/hsr2.1622
pii: HSR21622
pmc: PMC10568974
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1622Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Int J Cancer. 2015 Dec 15;137(12):2846-57
pubmed: 26095926
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Exp Suppl. 2018;108:153-176
pubmed: 30536171
J Contemp Dent Pract. 2019 Sep 1;20(9):1001-1002
pubmed: 31797818
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Cell. 2017 Jan 26;168(3):542
pubmed: 28129544
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
EBioMedicine. 2019 Jul;45:70-80
pubmed: 31255659
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Biochem Biophys Res Commun. 2021 Apr 9;548:60-66
pubmed: 33631675
Genome Biol. 2014 Mar 03;15(3):R47
pubmed: 24580837
Curr Opin Immunol. 2014 Feb;26:128-37
pubmed: 24556409
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Cell Biol Int. 2020 Sep;44(9):1890-1899
pubmed: 32437063
Cell Death Differ. 2021 Jul;28(7):2029-2044
pubmed: 34099897
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
PLoS One. 2013 Aug 09;8(8):e70429
pubmed: 23950933
Oral Oncol. 2020 Dec;111:104938
pubmed: 32739791
Cell Death Dis. 2014 Aug 21;5:e1382
pubmed: 25144717
Cell Host Microbe. 2015 Oct 14;18(4):463-70
pubmed: 26468749
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2152-62
pubmed: 18669583
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
J Hepatol. 2015 Sep;63(3):622-33
pubmed: 25931416
Cells. 2020 Oct 13;9(10):
pubmed: 33066292
Chin Med J (Engl). 2015 Oct 5;128(19):2638-45
pubmed: 26415803
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Clin Cancer Res. 2013 Mar 1;19(5):1197-203
pubmed: 23319825
BMC Cancer. 2011 Oct 11;11:437
pubmed: 21989116
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Immunother Cancer. 2019 Jul 17;7(1):189
pubmed: 31315674
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Cancer Immunol Res. 2019 May;7(5):737-750
pubmed: 30842092
Bioinformatics. 2007 Jul 15;23(14):1846-7
pubmed: 17496320
PLoS One. 2007 Nov 21;2(11):e1195
pubmed: 18030330
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Oncol Lett. 2020 Dec;20(6):377
pubmed: 33154775
Front Oncol. 2021 Feb 16;10:616952
pubmed: 33665167
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Asian J Surg. 2002 Jan;25(1):35-40
pubmed: 17585443
FASEB J. 2021 Aug;35(8):e21757
pubmed: 34233045
Eur J Cancer. 2021 May;148:382-394
pubmed: 33794440
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Cancer Sci. 2019 Aug;110(8):2620-2628
pubmed: 31152682